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Abstract 
Background: Osteoarthritis (OA) is a highly disabling and costly condition with an escalating prevalence in Australia 
due to the ageing and increasing obesity of the population. The general practitioner (GP) plays a central role in the 
management of this condition. The aim of this study was to examine opinions about the management of OA by Aus-
tralian GPs following the release of the Royal Australian College of General Practitioners Guideline for the non-surgical 
management of hip and knee OA (RACGP OA CPG), and to compare the results with an earlier survey administered by 
the National Prescribing Service.
Methods: In January 2013, a self-administered questionnaire was sent to 228 GPs to determine their treatment 
approaches to OA management using a clinical vignette of a patient with OA. This was compared with results from a 
similar survey undertaken in 2006.
Results: Seventy-nine GPs returned questionnaires (response rate 35 %). GP recommendations for paracetamol, a 
paracetamol/codeine compound, and oral non-steroidal anti-inflammatory drugs (NSAIDs) were consistent with rec-
ommendations in the RACGP OA CPG, and varied little from the previous survey. Notably, there was a marked increase 
between surveys in GP recommendations for tramadol (p = 0.004) and more potent opioids (p < 0.001). Advice about 
the adverse effects of NSAIDs and codeine and how to manage them increased between surveys (p = 0.038 and 
0.005, respectively). For all non-pharmacological treatments, there were only minor changes in the percentage of GP 
recommendations when compared with the previous survey, however they remain underutilised.
Conclusions: GPs generally demonstrated a conservative approach to the treatment of OA, however, the increased 
recommendations for more potent opioids warrants further investigation. Patients should be made aware of the risks 
of medications through the use of decision aids, which can provide structured guidance to treatment. Non-pharma-
cological interventions were not given the importance that is suggested by clinical practice guidelines.
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Background
Osteoarthritis (OA) is a chronic disease affecting more 
than 1.9 million Australians (nearly 9  % of the popula-
tion) with an annual health cost estimated at AUD$3.7 
billion [1]. Prevalence surveys suggest that more than 
50  % of the population aged over 65 have radiological 
evidence of OA, whilst it is universally present amongst 
those aged over 85 [2]. It is the sixth most common con-
dition managed by General Practitioners (GPs) in Aus-
tralia, accounting for 2.8 % of encounters [3], yet there is 
a paucity of detailed information about GP OA manage-
ment [4].
Despite a multitude of clinical practice guidelines 
(CPGs) for OA that have been developed both locally, 
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nationally and internationally, there is abundant evidence 
of suboptimal OA care [5]. Furthermore, the uptake of 
CPGs by health professionals is highly variable [6], most 
likely due to a range of barriers that have been variously 
ascribed to organisational, clinician and patient factors 
[7].
The aim of our present study was primarily to examine 
opinions about the management of OA by Australian GPs 
following the release in 2009 of the Royal Australian Col-
lege of General Practitioners Guideline for the non-surgi-
cal management of hip and knee OA (RACGP OA CPG) 
[8]. To our knowledge, no other studies have evaluated 
the impact of CPGs on the management of OA. A sec-
ondary objective was to compare these results with those 
from an earlier survey reported by the National Prescrib-
ing Service (NPS) [9].
Methods
This paper provides the results of a new GP survey and 
then compares them to the results of a previously pub-
lished survey.
Previously published NPS cross‑sectional survey (2006)
The survey was conducted by the National Prescribing 
Service Limited.
Target population
All Australian GPs.
Recruitment
The NPS did not publish recruitment details in 
their report and did not respond to requests for this 
information.
Survey instrument
The questionnaire used a clinical vignette of a hypotheti-
cal 79 year old woman with moderate to severe OA (see 
Fig.  1). Respondents were asked to describe what non-
pharmacological therapy they would initiate for her OA, 
the analgesic regimen they would use, and what informa-
tion about analgesic use they would provide her with. 
Response options to the 4-part questionnaire included 
yes/no answers and 1–4 line open-ended text.
Current CTA cross‑sectional survey (2013)
Target population
Australian GPs from New South Wales and South 
Australia.
Recruitment
The survey was conducted of GPs who had consented 
to participate in the CareTrack Australia (CTA) study, 
a population based study of the appropriateness of 
care [10]. GPs had been initially identified by randomly 
selected CTA patients who had been asked to name their 
treating GP for at least one of 22 selected conditions for 
the period 2009–2010, one of which was OA. The sub-
set of GPs treating CTA patients for OA was the target 
population. The survey was mailed to GPs in December 
2012, with AUD$150 paid as an incentive for comple-
tion. Reminder letters were sent with a set completion 
deadline of 31 January 2013. The return of questionnaires 
was considered to be implied consent to take part in the 
study.
Survey instrument
The new survey used the NPS questionnaire, modified to 
include two additional questions relating to GP workload.
Statistical analysis
Given a population of approximately 29,000 GPs in Aus-
tralia, the response of 79 provides, at worst, ±11 % accu-
racy for any dichotomous questionnaire item with 95 % 
confidence. Descriptive data are presented as counts and 
percentages, with ninety-five percent confidence inter-
vals. Comparison of results between the two surveys, 
and between GP demographics of the current survey and 
the Australian GP population was undertaken using Chi 
squared tests. All statistical analyses were undertaken 
using the Statistical Package for Social Scientists, version 
21 (SPSS, Chicago, IL, USA).
Ethics approval
Ethics approval was obtained from the Human Research 
Ethics Committee of the University of South Australia.
Results
Characteristics of respondents
There were 79 responses to a mail-out of 228 question-
naires (response rate 35  %). Respondents were margin-
ally older than the Australian GP population, the gender 
composition was identical, and their practice size was 
larger (see Table  1). The mean number of years since 
graduation was 28.2 (SD  =  10.5), the mean number of 
OA patients seen per week was 21.1 (SD = 16. 9) and the 
mean weekly hours worked in clinical practice was 34.2 
(SD = 13.7).
Pharmacological therapies
Table  2 shows the pharmacological therapies recom-
mended for the hypothetical patient vignette.
Given that the vignette stated that the patient’s usual 
paracetamol and meloxicam (7.5 mg a day) drug therapy 
was ineffective, three quarters of respondents (75 %) rec-
ommended a change to slow release paracetamol tablets 
(2 ×  665  mg) to be taken 3 times a day. Nearly all GPs 
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(96 %) selected paracetamol or the compound paraceta-
mol/codeine medication. All GPs who chose codeine 
(mainly 30 mg, as needed) also selected paracetamol.
In our 2013 survey, a high percentage of GPs (86  %) 
suggested supplementing paracetamol (often with 
codeine) with NSAIDs. In recommending NSAIDS, 
over two-thirds of GPs (67 %) chose meloxicam (mainly 
7.5 mg, once daily when required). Ten percent selected 
other NSAIDs (including ibuprofen, diclofenac and nap-
roxen) and 6 % selected other COX-2 selective NSAIDs 
such as celecoxib. Only one GP nominated a topical 
NSAID.
Notably, tramadol was recommended by nearly one-
third of GPs (30 %) with 20 % choosing 50–100 mg (2–4 
times daily when required) and 10  % selecting the slow 
release option (100–150  mg once or twice daily, regu-
larly). In all responses, tramadol was to be used with 
paracetamol.
Nine percent of GPs selected oxycodone and 11  % 
selected buprenorphine or fentanyl patches, with 3  % 
Maria, an active 79 year old (BMI 23 kg/m2), was diagnosed with osteoarthritis 20 
years ago. For the past 2 years, her osteoarthritic pain has been controlled with 
paracetamol and meloxicam (both initiated by her GP). All medical conditions except 
osteoarthritis are well controlled. Recent investigations (electrolytes, lipids, renal and 
liver function, full blood count) are normal. 
Current medications: 
paracetamol 1 g four times/day (osteoarthritis) 
meloxicam 7.5 mg in the morning on ‘bowls’ days (osteoarthritis) 
verapamil 240 mg/day; and atenolol 50 mg/day (hypertension – BP 133/85 mmHg) 
fenofibrate 134 mg/day (hypertriglyceridemia) 
latanoprost plus timolol 1 drop/eye at night (glaucoma) 
amitriptyline 10 mg at night (insomnia) 
docusate plus senna 2 at night when required (constipation) 
Other information: Nil drug or food allergies, history of gastrointestinal disease or 
diabetes. Eyesight is fair. 
Her knee pain has increased in the past few months; it is moderate on waking and 
improves as she first starts moving. It worsens through the day to moderate and 
occasionally severe, especially with prolonged walking or standing. On examination, 
bony swelling is evident on both knees, and there is tenderness and crepitus on her 
right knee. Remaining physical examination is unremarkable. 
According to Maria, paracetamol has been effective but ‘wears off’ quite quickly. 
Meloxicam helps but lately her knee has occasionally prevented her from playing 
bowls. She asks you to recommend ‘something stronger’ to ‘help her knee pain’ so 
that she can return to bowls. 
Fig. 1 Clinical vignette
Page 4 of 8Basedow et al. BMC Res Notes  (2015) 8:536 
(n = 2) choosing to solely use these opioids. All GPs who 
recommended these stronger opioids acknowledged the 
risks associated with their use (potentially addictive, and 
may cause constipation and confusion).
Thirteen percent of GPs chose glucosamine and/or 
chondroitin. In all instances, these complementary and 
alternative medicines (CAM) were selected together with 
paracetamol and an NSAID. Of the miscellaneous phar-
macological options selected by GPs, fish or krill oil was 
chosen by 13 % of GPs, and intra-articular corticosteroid 
injection by 10 %. No GPs nominated viscosupplements 
(hyaluronic acid).
The major differences between the 2006 NPS survey 
and the 2013 CTA survey were increases in the recom-
mended use of tramadol (p  =  0.004) and more potent 
opioids (oxycodone, morphine and buprenorphine) 
(p < 0.001), and a decrease in recommendations for glu-
cosamine and chondroitin (p  <  0.001), topical NSAIDS 
(p = 0.032) and codeine (p < 0.001).
Non‑pharmacological therapies
Table 3 shows the non-pharmacological therapies recom-
mended for the hypothetical patient vignette.
Over half the respondents (56  %) recommended one 
or two non-pharmacological therapies and 44 % selected 
more than two. The most commonly recommended com-
bination was physiotherapy and exercise therapy includ-
ing hydrotherapy (33  %). Heat therapy for symptomatic 
OA relief was universally favoured over cold therapy (21 
vs. 0 %). Several GPs (17 %) nominated referral for joint 
replacement.
There were only minor changes in recommendations 
for non-pharmacological therapies between the two sur-
veys, and none were statistically significant.
GP advice to patients
Table  4 presents a summary of recommended advice to 
be provided to the patient about analgesic use.
In the 2013 survey, GPs were much less likely 
to include the need to take medications regularly 
(p < 0.001). Advice about the adverse effects of NSAIDs 
and codeine and how to manage them increased from 
21  % in 2006 to 45  % in 2013 (p  <  0.001). GPs were 
far more likely to consider recommending stronger 
analgesics if needed in future (p  <  0.001). Nonethe-
less, paracetamol was still considered the safest option 
Table 1 Gender, age group and  practice size of  GP 
respondents
Respondents Australian GP popu‑
lation [3, 34, 35]
Signif.
n % n %
Gender 0.921
 Female GPs 33 42 12,095 42
 Male GPs 46 58 16,916 58
 Total 79 100 29,011 100
Age group 0.009
 <44 15 19 9831 33
 45–64 48 61 15,449 54
 65 or greater 16 20 3731 12
 Total 79 100 29,011 100
Practice size <0.001
 Solo 2 3 2456 35
 2–5 22 29 3075 44
 6 or greater 52 68 1504 21
 Total 76 100 7035 100
Table 2 Recommended pharmacological therapies for the hypothetical patient vignette
a Respondents may have more than one response
Drug Number and percentage of  
respondentsa (n = 200)
Number and percentage of  
respondentsa (n = 79)
Signif.
2006 2013
n % 95 % CI n % 95 % CI
Paracetamol (including slow release option) 190 95 91–97 72 91 83–96 0.349
Oral NSAID (conventional or COX-2 selective) 160 80 74–85 66 84 74–91 0.610
Topical NSAID (conventional or COX-2 selective) 19 10 6–14 1 1 0–6 0.032
Tramadol 29 15 10–20 24 30 21–42 0.004
Opioids–paracetamol plus codeine 28 14 9–20 14 18 10–28 0.550
Opioids–codeine 65 33 26–39 5 6 2–14 <0.001
Opioids–oxycodone, morphine or buprenorphine 10 5 3–9 16 20 12–31 <0.001
Intra-articular injections 12 6 4–10 8 10 5–19 0.344
Glucosamine and/or chondroitin 78 39 33–46 10 13 6–22 <0.001
Fish or krill oil 11 6 3–9 10 13 7–22 0.074
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(p  <  0.001). In both surveys, very few GPs chose to 
advise the patient about the need to avoid other prepa-
rations containing paracetamol and the importance of 
checking with health professionals before taking over-
the-counter medications as a safeguard against poten-
tial drug interactions.
Discussion
Pharmacological therapies
The scenario provided was for an elderly lady who was 
currently on paracetamol and meloxicam for her OA. She 
also suffered from insomnia, constipation, hypertension, 
hypertriglyceridemia and glaucoma. Interestingly, rela-
tively few GP responses discussed these comorbid condi-
tions, or commented on how these might impact on her 
treatment, despite the importance placed on such factors 
by recent guidelines [11].
Paracetamol and a paracetamol/codeine combination 
used in an optimised and regular dosage regimen were 
the primary analgesics of choice recommended by GPs 
(96  %), although evidence suggests that patients may 
underestimate the value of paracetamol due to a per-
ception of ineffectiveness and a failure to appreciate the 
benefits of long-term use [12]. In view of this, GPs have a 
crucial role in educating patients about the pivotal role of 
paracetamol in ameliorating pain.
NSAIDs were recommended by most GPs (86 %), who 
also recognised the importance of monitoring the risk 
factors associated with their use. Combining an NSAID 
with paracetamol—as most GPs recommended, allows 
the use of a lower NSAID dose, thereby reducing the 
risk of adverse effects [13]. Whilst there is no evidence 
to support one oral NSAID over another with regard to 
efficacy [14], it was notable that fewer GPs endorsed the 
use of topical NSAIDs when compared with the previous 
survey, despite evidence supporting their effectiveness, 
particularly for those aged over 75 [15]. The underutilisa-
tion of topical NSAIDs has been previously reported [16] 
and is consistent with the findings of the CTA study [10].
Recommendations by GPs for tramadol use have dou-
bled since the 2006 NPS survey [17], reflective of its 
effectiveness in treating moderate to severe pain. Never-
theless, adverse drug reactions are common, particularly 
in the elderly, and the potential for serious drug–drug 
interactions should not be underestimated [18].
The GPs in our survey recommended using more 
potent opioids (oxycodone, morphine and buprenor-
phine), and this has also increased significantly since the 
previous survey [17]. In addition to modest benefits and 
the high risk of adverse effects, their use was not indi-
cated based on the clinical scenario provided. Accord-
ing to the RACGP OA CPG, more potent opioids should 
be reserved for severe OA when joint-replacement sur-
gery is delayed or contraindicated [8]. Researchers have 
elsewhere commented on the increasing level of GP 
prescribing of opioids in OA management [19]; further 
investigation is clearly warranted.
Glucosamine and chondroitin are the most commonly 
used CAM treatments for OA [20], however, there is 
no evidence of their clinical efficacy. Recent RCTs have 
shown that glucosamine has a similar effect to pla-
cebo on pain, with commercially funded trials having 
larger effects than industry-independent trials [21]. The 
percentage of GPs recommending their use was only 
Table 3 Recommended non-pharmacological therapies for the hypothetical patient vignette
a Respondents may have more than one response
b There was an occasional missing value
c Unknown
Therapy Number and percentage of  
respondentsa,b (n = 193)
Number and percentage of  
respondentsa,b (n = 78)
Signif.
2006 2013
n % 95 % CI n % 95 % CI
Physiotherapy 115 60 53–66 42 54 42–65 0.451
Land-based exercise 77 40 33–47 36 46 35–58 0.610
Hydrotherapy 78 40 34–47 24 31 21–42 0.179
Heat and cold therapies 57 30 24–36 16 21 12–31 0.173
Referral for joint replacement 37 19 14–25 13 17 10–26 0.758
Knee taping/bracing and insoles 21 7 4–12 5 6 2–14 0.366
Weight loss 15 8 5–13 4 5 1–13 0.611
Tai chi c c 4 5 2–12 c
Acupuncture 13 7 4–11 3 4 1–11 0.529
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one-third of that in the previous NPS survey [17], per-
haps reflecting an increased awareness by GPs of their 
ineffectiveness.
A high percentage of GPs recommended fish oil and 
krill oil in spite of the fact that their early promise has not 
been realised, and there is no evidence of clinical efficacy 
in well-designed studies [22]. No herbal therapies were 
recommended by GPs.
Intra-articular corticosteroid injections can provide 
rapid symptomatic relief, however, their short benefit 
duration (up to 4  weeks) and cost may limit their value 
for chronic diseases such as OA [23]. The recent deletion 
of the scheduled item number (50124) for joint injection 
by Medicare, the Australian government’s medical insur-
ance scheme for primary health care, may have influ-
enced the GPs’ decisions not to recommend this therapy. 
Additionally, lack of training or confidence in their abil-
ity to perform intra-articular injections, or a belief in the 
superiority of patient outcomes with image guided injec-
tions, may have affected their choice.
Non‑pharmacological therapies
For all non-pharmacological treatments, there were only 
minor changes in the percentage of GP recommenda-
tions when compared with the 2006 survey. A major-
ity of GPs recommended a multi-disciplinary approach 
incorporating various combinations of physiotherapy, 
exercise and hydrotherapy, although these interventions 
were not given the importance that is suggested by the 
RACGP OA CPG. For example, although exercise has 
similar effect sizes to simple analgesic and NSAIDs but 
with fewer contraindications or adverse effects [21], it 
Table 4 Recommended information to be provided to patient about analgesic use
a Respondents may have more than one response
b There was an occasional missing value
Information Number and percent‑
age of respondentsa,b 
(n = 199)
Number and percent‑
age of respondentsa,b 
(n = 70)
Signif.
2006 2013
n % 95 % CI n % 95 % CI
Dosing advice
 Taking medication regularly by clock 126 63 56–70 27 39 28–50 <0.001
 Use analgesics pre-emptively (e.g. before playing bowls or before strenuous exercise) 33 17 12–22 6 9 4–17 0.150
 NSAID to be taken on an ‘as required’ basis 24 12 8–17 5 7 3–16 0.359
 When and how to take analgesics on an ‘as required’ basis 13 7 4–11 3 4 1–12 0.697
 NSAID to be taken with or after food 12 6 3–10 3 4 1–12 0.807
 Maximum of 4 g of paracetamol in a day 7 4 2–7 1 1 0–8 0.634
 Ensure adequate dosage of analgesics is taken 7 4 2–7 6 9 4–17 0.170
 Paracetamol Slow Release offers a more convenient option if preferred 7 4 2–7 0 0 0 0.249
 Use lowest effective dose 6 3 1–6 6 9 4–17 0.110
Awareness and management of adverse effects
 Adverse effects of medications (in general) 35 18 13–23 5 7 3–16 0.055
 Adverse effects of NSAIDs (e.g. gastrointestinal bleeding, increased blood pressure) 32 16 12–22 20 29 19–40 0.038
 Potential opioid-induced constipation and strategy for managing constipation 30 15 11–21 6 9 4–17 0.242
 Adverse effects of codeine (e.g. constipation, risk of dependency) 9 5 2–8 11 16 9–26 0.005
 Risk of drowsiness with opioid medications 6 3 1–6 3 4 1–12 0.610
Follow-up
 Regular follow-up to assess efficacy and titrate doses 23 12 8–17 5 7 3–16 0.416
Potential drug interactions
 Avoid other preparations containing paracetamol 10 5 3–9 1 1 0–8 0.339
 Drug interactions (in general) 6 3 1–6 1 1 0–8 0.779
 Check with health professional before taking over-the-counter medications 5 3 1–6 2 3 1–10 0.779
Role and place of different analgesics
 Options of stronger analgesics if required in future 18 9 6–14 22 31 22–43 <0.001
 Paracetamol is the safest option 13 7 4–11 18 26 17–37 <0.001
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was recommended by only just over half the GPs. Previ-
ous research has highlighted the gap between evidence-
based recommendations for care and the uptake of 
non-pharmacological interventions [24]. In a recent large 
scale cross-sectional study of GP management of hip and 
knee OA in Australia, Brand and colleagues confirmed 
the suboptimal use of non-pharmacological therapies for 
OA [4].
While there is some evidence that the Australian gov-
ernment’s introduction of GP funding incentives for 
chronic disease management involving allied health pro-
fessionals has been associated with positive outcomes 
[25], there clearly is scope for greater use of non-pharma-
cological therapies, in line with CPG recommendations.
Heat therapy was supported by around 1 in 5 GPs not-
withstanding the lack of evidence for its efficacy. Its role 
in reducing pain and enabling a resumption of physi-
cal activity may be seen by GPs as being helpful. There 
was no support amongst surveyed GPs for cold therapy, 
despite some evidence that it reduces swelling, and 
improves range of motion, knee strength and function 
[26].
The RACGP OA CPG only cautiously recommended 
tai chi [8], however, Arthritis Research UK have recently 
reported a number of randomised controlled trials that 
support its effectiveness in treating OA of the knee [27]. 
Only 5 % of GPs in our survey recommended that their 
patients initiate tai chi.
Several GPs considered acupuncture as a worthwhile 
option, but it has been reported that its putative ben-
efits are most likely attributable to placebo effects [28]. A 
recent CPG issued by the American College of Rheuma-
tology, however, conditionally recommended acupunc-
ture for patients with moderate to severe pain and for 
whom surgery is either not desired or is contraindicated 
[15].
GP advice to patients
The provision of inadequate analgesic information to OA 
patients by GPs has been previously reported [29]. In the 
current study, GPs emphasised the importance of advice 
on appropriate dosing, yet research has highlighted the 
reluctance by patients to take painkillers at the prescribed 
dosage and frequency [30]. Whilst there has been a 
noticeable improvement between the 2006 and 2013 sur-
veys in the percentage of GPs providing advice about the 
adverse effects of NSAIDs and codeine, there is evidence 
that many patients still don’t adequately understand the 
risks associated with use [31]. Shared decision making 
between patients and their GPs through the use of deci-
sion aids should be encouraged. The Cochrane Musculo-
skeletal Group, for example, has developed easy-to-use 
decision algorithms which prepare patients for consul-
tations by explaining options, quantifying the risks and 
benefits and providing structured guidance to treatment 
[32]. The challenge for GPs is how best to integrate such 
tools into routine care, which will necessitate changing 
some work practices, and will inevitably be inconvenient 
for busy clinicians [33].
Limitations
There were several limitations to our study. Firstly, 
because of the comparatively small sample size, the gen-
eralizability of results should be treated with caution. GPs 
in our study were found to be broadly similar in terms of 
gender, however, they were relatively older than the Aus-
tralian GP population and general practices in our study 
were larger.
Secondly, the 35  % response rate to our survey was 
low. Although poor response rates have been observed 
in many GP studies [36], there was clearly a potential for 
selection bias.
Finally, there were some difficulties with our study 
associated with use of the 2006 NPS survey. For exam-
ple, we were unable to obtain the recruitment methods 
for this survey, nor did we have any demographic details 
of survey participants. This limited our ability to make 
further comparisons between the 2006 and 2013 sur-
veys. There were also no questions in the NPS survey that 
related to the provision of self-management and lifestyle 
advice, which are recognized in CPGs as essential fea-
tures of appropriate OA management.
Conclusions
Despite the existence of CPGs for the best practice man-
agement of OA, our study has highlighted a diversity of 
therapeutic approaches for a typical case. There have 
been some change in GP treatment recommendations 
following the release of the RACGP OA CPG, however, 
it is not possible to infer a causal relationship. Tramadol 
and more potent opioids appear to be more commonly 
favoured than previously; the latter, in particular, war-
rants further investigation, as its use does not appear to 
be in accord with CPG recommendations. Furthermore, 
whilst there have been only minor changes in recommen-
dations for the non-pharmacological treatment of OA, it 
would appear that GPs are still not giving these options 
the attention that is warranted.
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